Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

October 05, 2015 11:25 AM ET

Capital Markets

Company Overview of Ampersand Capital Partners

Company Overview

Ampersand Capital Partners is a private equity firm specializing in growth equity, expansion, recapitalizations, management buyouts and corporate divestitures. It invests in lower middle market companies. The firm typically invests in healthcare and industrial sector. Within industrial sector, it focuses on product and process design software, instrumentation for the chemical processing and environmental industries. Within healthcare sector, the firm focuses on laboratory services, diagnostic testing, regulatory testing, manufacturing support; laboratory products, scientific products, diagnostic products, specialty distribution; contract manufacturing, medical Devices and components, nutriti...

55 William Street

Suite 240

Wellesley, MA 02481

United States

Founded in 1988





Key Executives for Ampersand Capital Partners

Founder and Managing Partner
Age: 63
Chief Financial Officer and Chief Compliance Officer
Director of Operations
Managing Partner and Managing General Partner
Age: 50
General Counsel
Age: 53
Compensation as of Fiscal Year 2015.

Ampersand Capital Partners Key Developments

Avista Pharma and ATS Labs Seeks Acquisitions

Ampersand Capital Partners said it has appointed Patrick D. Walsh as Chief Executive Officer of Avista Pharma Solutions and ATS Labs, Inc. He will focus on expanding the service offerings of the combined business and evaluating additional acquisition opportunities.

Ampersand Capital Partners Announces Executive Appointments

Ampersand Capital Partners announced that it has appointed Patrick D. Walsh as Chief Executive Officer of Avista Pharma Solutions and Accuratus Labs. In conjunction with Mr. Walsh's appointment, Eric Hess has been named President and Chief Business Officer of the Accuratus Labs business unit. Mr. Walsh has over 30 years of experience building high-achieving, contract development and manufacturing organizations serving the pharmaceutical industry. He will focus on expanding the service offerings of the combined business and evaluating additional acquisition opportunities. Mr. Walsh has led several high growth organizations over the course of his career including as CEO of AAI Pharma Services, CEO of Kadmus Pharmaceuticals, and president and COO of Gensia Sicor. In addition to his executive experience, Mr. Walsh has served on the boards of directors of various companies in the pharmaceutical, biotechnology, and contract service and manufacturing industries.

Similar Private Companies By Industry

Company Name Region
Livingstone Partners LLC United States
Starboard Capital Markets United States
Paychex Securities Corporation United States
Note Orius, Inc. United States
The Legend Group, Inc. United States

Recent Private Companies Transactions

June 18, 2015
Protein Technologies, Inc.
Private Placement
December 16, 2014
CutisPharma Inc.
October 29, 2014
ChanTest Corporation

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Ampersand Capital Partners, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at